Skip to main content
SpringerLink
Log in

Optimism in public biotech rises as credit crunch recedes

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Percentage of biotech firms operating with less than one year's cash, segmented by market cap.

Author information

Authors and Affiliations

  1. Business Editor,

    Brady Huggett

Authors
  1. Brady Huggett
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huggett, B. Optimism in public biotech rises as credit crunch recedes. Nat Biotechnol 28, 5–6 (2010). https://doi.org/10.1038/nbt0110-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0110-5

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation